Dmitriy Zamarin, MD, PhD, is the Section Head of Gynecologic Medical Oncology and is a member of the Icahn Genomics Institute and the Precision Immunology Institute at the Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai. He is a medical oncologist specializing in the care of women with gynecologic cancers, including cervical, ovarian, and endometrial cancers.

Dr. Zamarin obtained his MD and PhD degrees from the Mount Sinai School of Medicine. He completed residency in Internal Medicine at the Mount Sinai Hospital and fellowship in Hematology/Oncology at the Memorial Sloan Kettering Cancer Center, where his research was focused on the mechanisms of response and resistance to cancer immunotherapy and development of novel immunotherapy treatment approaches. He has spent a decade as a faculty and Translational Research Director in Gynecologic Medical Oncology at the Memorial Sloan Kettering Cancer Center before transitioning to his current role in September of 2023. 

Dr. Zamarin has served as a principal investigator and a translational chair on multiple institutional and cooperative group clinical trials exploring novel immunotherapy combinations in gynecologic cancers and other solid tumors and serves as the translational research co-chair on the NRG Oncology Cervical Cancer committee. In the laboratory, his research is focused on understanding of the mechanisms by which gynecologic cancers are recognized by the immune system and on identification of biomarkers predictive of response and resistance to immunotherapy. His laboratory uses mouse models to explore the mechanisms of tumor-immune system interactions and to develop novel therapeutics, with particular focus on oncolytic viruses, vaccines, and targeted therapies. For his work Dr. Zamarin has received awards and funding from multiple organizations including Damon Runyon Foundation, Ovarian Cancer Research Alliance, Department of Defense, and R01 grants from the National Cancer Institute.